Israeli burn and wound treatment biopharmaceutical company MediWound announced this week that it signed a distribution agreement with UAE-based international conglomerate Ghassan Aboud Group (GAG) to expand the global presence of its product NexoBrid for the treatment of severe burns.
The commercialization of NexoBrid in the UAE will begin after regulatory approval is secured, the company said, a process that is expected to occur within the year.
Founded in 2000, MediWound is a biotech company focused on developing, manufacturing, and commercializing products for the treatment of severe burns and chronic wounds. Its first product NexoBrid is a topically administered biological product that enzymatically removes eschar (nonviable burn tissue) in patients with deep partial and full-thickness thermal burns within four hours of application. It does not harm viable tissue.
In July, the company submitted its product for marketing approval by the US Food and Drug Administration (FDA), and hopes to obtain clearance by June 2021. The product was approved by the European Medicines Agency (EMA) in 2012.
“We are proud to enter into our first partnership in the Middle East, and believe that, together with GAG, we will be able to open up new opportunities for NexoBrid across the region, providing burn specialists with a new paradigm for the treatment of severe burns, which can improve patients’ lives and the quality of their care,” said MediWound CEO Sharon Malka.
Ghassan Aboud, Chairman of Ghassan Aboud Group stated: “We are pleased to partner with MediWound to bring NexoBrid to our markets in the UAE. Our goal is always to pioneer, excel and make an impact, which we have been doing so for 26 years now. I am certain that with our extensive distribution network and market reach, and with MediWound’s innovative drug we will be able to improve the standard of care of burn patients and I strongly believe NexoBrid will be an instrumental part of the future treatment for burn patients everywhere.”